Literature DB >> 12566929

Differential regulation of glutamate receptors in Alzheimer's disease.

Hyoung-gon Lee1, Xiongwei Zhu, Hossein A Ghanbari, Osamu Ogawa, Arun K Raina, Micheal J O'Neill, George Perry, Mark A Smith.   

Abstract

Selective neurodegeneration is a prominent feature in Alzheimer's disease; however, the mechanism of neuronal death is still unclear. Nonetheless, the topographical distribution of different types of receptors is thought to contribute to the regional selective nature of neuronal degeneration. Specifically, since glutamatergic transmission is severely altered by the early degeneration of cortico-cortical connections and hippocampal projections in Alzheimer's disease, we suspect that glutamate receptors may play a new role in the pathophysiology of disease. Here we review the salient aspects of glutamate receptor expression in Alzheimer's disease and how their differential regulation can contribute to the selective neurodegeneration seen in the disease. Additionally, we assess the potential therapeutic value of glutamate receptors as a target for drug intervention in Alzheimer's disease. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12566929     DOI: 10.1159/000067427

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  8 in total

1.  The unfolded protein response regulates glutamate receptor export from the endoplasmic reticulum.

Authors:  Jaegal Shim; Tohru Umemura; Erika Nothstein; Christopher Rongo
Journal:  Mol Biol Cell       Date:  2004-08-18       Impact factor: 4.138

2.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

3.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

Review 4.  Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.

Authors:  Wagner Carbolin Martins; Carla Inês Tasca; Helena Cimarosti
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

5.  A method for the prediction of GPCRs coupling specificity to G-proteins using refined profile Hidden Markov Models.

Authors:  Nikolaos G Sgourakis; Pantelis G Bagos; Panagiotis K Papasaikas; Stavros J Hamodrakas
Journal:  BMC Bioinformatics       Date:  2005-04-22       Impact factor: 3.169

6.  Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.

Authors:  Lutz Frölich; Glen Wunderlich; Claus Thamer; Michael Roehrle; Miguel Garcia; Bruno Dubois
Journal:  Alzheimers Res Ther       Date:  2019-02-12       Impact factor: 6.982

7.  Effects of protopanaxatriol-ginsenoside metabolites on rat N-methyl-d-aspartic Acid receptor-mediated ion currents.

Authors:  Tae-Joon Shin; Sung-Hee Hwang; Sun-Hye Choi; Byung-Hwan Lee; Jiyeon Kang; Hyeon-Joong Kim; R Suzanne Zukin; Hyewhon Rhim; Seung-Yeol Nah
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

8.  Disrupting GluA2-GAPDH Interaction Affects Axon and Dendrite Development.

Authors:  Frankie Hang Fung Lee; Ping Su; Yu-Feng Xie; Kyle Ethan Wang; Qi Wan; Fang Liu
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.